- Supported exchanges /
- NASDAQ /
- ACTU.NASDAQ
Actuate Therapeutics, Inc. Common stock (ACTU NASDAQ) stock market data APIs
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Actuate Therapeutics, Inc. Common stock Financial Data Overview
| 8.98 | |
| 8.922 | |
| - | |
| 9 | |
| 8.75 | |
| 5.51-10.162 | |
| 153 M | |
| 19 112 K | |
| 0 | |
| -0.3365 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Actuate Therapeutics, Inc. Common stock Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share -1.85
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Actuate Therapeutics, Inc. Common stock Earnings via APIs
- Latest Release 2024-08-28
- EPS/Forecast NaN
Get Actuate Therapeutics, Inc. Common stock End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
